Solesence, Inc. (SLSN), formerly Nanophase Technologies Corporation, is a Romeoville, Illinois-based developer and manufacturer of mineral-based skincare and sun-care products, including surface-engineered zinc oxide and titanium dioxide ingredients. As a NASDAQ-listed micro-cap with a market capitalization of roughly $63 million, the company occupies a small, specialized niche within the household and personal products industry.
Solesence does not have a meaningful set of credible, current numeric analyst price targets to aggregate. MarketBeat reports a consensus price target of "N/A" with a single "Sell" rating on file, while Zacks Investment Research initiated coverage with an Underperform recommendation and Weiss Ratings has maintained a "Sell"-type qualitative rating. One third-party feed showing an extremely high "average target" is clearly a data-entry artifact and is excluded from this analysis.
Because no usable analyst targets exist, the central target is not an analyst consensus. Instead, it reflects a publicly discussed, verifiable milestone: the $1.00 level. NASDAQ generally requires listed companies to maintain a minimum closing bid price of $1.00, and Fidelity's quote page flags SLSN as having failed to meet NASDAQ continued listing requirements. Regaining and holding the $1.00 mark therefore carries concrete compliance significance beyond its role as a psychological round-number level.
The most recent verified price for SLSN is approximately $0.90, with the stock trading in a 52-week range of roughly $0.61 to $3.17. Reaching $1.00 requires an upside of about 11%, a modest move by percentage standards but one that still demands sustained buying in a thinly traded micro-cap.
The path toward $1.00 likely runs through improved quarterly results and clearer progress on listing compliance. The company reports trailing-twelve-month revenue of about $55.4 million against a net loss of roughly $2.9 million, with diluted EPS (earnings per share) of approximately -$0.04. A return to profitability, or at least a narrowing loss with revenue stabilization, would give investors a firmer fundamental basis to support the shares.
The strongest support for a move to $1.00 is its dual role as a listing-compliance threshold and a psychological anchor. If management communicates a credible plan to regain NASDAQ compliance, investor attention could concentrate on that milestone. Solesence's positioning in mineral-based, "clean" skincare also aligns with durable consumer trends, and its proprietary Active Stress Defense technology provides differentiation in the sun-care and personal-care markets. A revenue base above $50 million shows the company is not a pre-revenue development-stage business, even if profitability remains elusive.
Several factors could keep the shares below $1.00. The company has posted net losses and carries negative EPS, with a thin cash balance of roughly $1.05 million and a debt-to-equity ratio near 172%, leaving limited financial cushion. The disclosed NASDAQ deficiency raises the risk of delisting proceedings if the bid price does not recover. As a micro-cap with low average volume, the stock is also vulnerable to sharp swings on modest trading activity, and the caution expressed in available ratings suggests sentiment remains skeptical.
The $1.00 mark sits just above the current price and represents both a psychological level and a compliance threshold, making it a natural focal point. Below it, recent trading has found support in the $0.85–$0.86 area. The 52-week high near $3.17, reached in late 2025, underscores how far the stock has fallen, while the 52-week low near $0.61, set in mid-2026, marks the downside extreme. A sustained close above $1.00 would be a meaningful structural change, while repeated failure at that level could reinforce it as resistance.
Because the $1.00 target is tied to a listing-compliance milestone rather than a formal analyst research horizon, no single 12-month assumption applies. Investors should watch the company's next earnings release, scheduled for November 12, 2026, along with any statements from management about NASDAQ compliance, revenue trends, margin progress, and cash position. Corporate announcements regarding listing status and any reverse-stock-split considerations, which are common compliance tools, would be especially relevant to the $1.00 objective.
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on shifting market conditions, technical behavior, and AI-driven analysis. For a volatile micro-cap like Solesence, such tools can help traders spot changing trends and monitor positions more efficiently without manually reviewing every chart. Traders seeking to identify opportunities and react to momentum shifts can use these signals as part of a broader research process.
The question of whether Solesence (SLSN) can reach $1.00 is less about analyst conviction — there is effectively none to measure — and more about a compliance-driven, psychological milestone. At roughly $0.90, the required move is a modest 11%, but it must be achieved against continued losses, a thin cash position, high leverage, and a disclosed listing deficiency. The strongest supports are the concrete significance of $1.00 for NASDAQ compliance and the company's alignment with durable clean-skincare demand. The principal obstacles are financial fragility and weak sentiment. Investors should monitor earnings, listing-status communications, and whether the stock can hold above the $0.85 support zone, while recognizing that no outcome is guaranteed.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor tells us that SLSN and NWL have been poorly correlated (+14% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that SLSN and NWL's prices will move in lockstep.
| Ticker / NAME | Correlation To SLSN | 1D Price Change % | ||
|---|---|---|---|---|
| SLSN | 100% | -9.76% | ||
| NWL - SLSN | 14% Poorly correlated | -4.59% | ||
| NUS - SLSN | 11% Poorly correlated | -2.58% | ||
| HELE - SLSN | 10% Poorly correlated | -5.29% | ||
| CNEY - SLSN | 10% Poorly correlated | -13.41% | ||
| HNST - SLSN | 9% Poorly correlated | -6.08% | ||
More | ||||
| Ticker / NAME | Correlation To SLSN | 1D Price Change % |
|---|---|---|
| SLSN | 100% | -9.76% |
| Household/Personal Care industry (30 stocks) | -1% Poorly correlated | -4.05% |